Navigation Links
Oncothyreon to present at BIO Investor Forum 2008
Date:10/24/2008

SEATTLE, Oct. 24 /PRNewswire-FirstCall/ - Oncothyreon Inc. (Nasdaq: ONTY) (TSX:ONY), a biotechnology company specializing in the development of innovative therapeutic products for the treatment of cancer, today announced that Robert Kirkman, M.D., President and Chief Executive Officer, is scheduled to present at the 7th Annual BIO Investor Forum in San Francisco on Friday, October 31, 2008 at 8:00 a.m. Pacific Time.

A live and archived webcast of Dr. Kirkman's presentation can be accessed at http://www.oncothyreon.com under the "News & Events" section.

About Oncothyreon

Oncothyreon is a biotechnology company specializing in the development of innovative therapeutic products for the treatment of cancer. Oncothyreon's goal is to develop and commercialize novel synthetic vaccines and targeted small molecules that have the potential to improve the lives and outcomes of cancer patients. For more information, visit http://www.oncothyreon.com.


'/>"/>
SOURCE Oncothyreon Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Oncothyreon announces receipt of NASDAQ letter regarding compliance with NASDAQ Global Market listing standards
2. Oncothyreon announces prioritization plan for development programs
3. Oncothyreon announces receipt of notice of non-compliance with market value of listed securities standard for listing on The NASDAQ Global Market
4. Oncothyreon initiates Phase 1 trial of PX-866 cancer compound
5. Oncothyreon initiates Phase 1b trial of PX-12 in patients with advanced metastatic cancer
6. Oncothyreon to receive milestone payment
7. Oncothyreon Reports First Quarter 2008 Financial Results
8. Oncothyreon files investigational new drug application for PX-866 oncology compound
9. Data for Oncothyreons PX-12 and PX-866 presented at AACR Annual Meeting
10. Oncothyreon announces data from multiple small molecule programs to be presented at American Association of Cancer Research Annual Meeting
11. Oncothyreon announces effectiveness of shelf registration statement
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... ... October 11, 2017 , ... At its national board meeting ... I. Sheikh, the co-founder, CEO and chief research scientist of Minnesota-based Advanced Space ... membership in ARCS Alumni Hall of Fame . ASTER Labs is a ...
(Date:10/11/2017)... ... October 11, 2017 , ... Personal eye wash is a basic first aid supply for any ... So which eye do you rinse first if a dangerous substance enters both eyes? It’s ... Wash with its unique dual eye piece. , “Whether its dirt and debris, or ...
(Date:10/11/2017)... BALTIMORE, Md. (PRWEB) , ... October 11, 2017 ... ... for digital pathology, announced today it will be hosting a Webinar titled, “Pathology ... of  Advanced Pathology Associates , on digital pathology adoption best practices and how ...
(Date:10/11/2017)... LAGUNA HILLS, Calif. , Oct. 11, 2017 ... London (ICR) and University of ... prognostic tool to risk-stratify patients with multiple myeloma (MM), in ... nine . The University of Leeds ... by Myeloma UK, and ICR will perform the testing services ...
Breaking Biology Technology:
(Date:5/16/2017)... , May 16, 2017   Bridge Patient ... organizations, and MD EMR Systems , an ... partner for GE, have established a partnership to ... product and the GE Centricity™ products, including Centricity ... These new integrations will allow ...
(Date:4/17/2017)... NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or the ... Annual Report on Form 10-K on Thursday April 13, 2017 with ... ... Relations section of the Company,s website at http://www.nxt-id.com  under "SEC ... . 2016 Year Highlights: Acquisition ...
(Date:4/11/2017)... , April 11, 2017 No two ... researchers at the New York University Tandon School ... Engineering have found that partial similarities between prints ... used in mobile phones and other electronic devices ... The vulnerability lies in the fact that ...
Breaking Biology News(10 mins):